546 related articles for article (PubMed ID: 8946941)
21. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene.
Heufelder AE; Bahn RS
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1420-32. PubMed ID: 7775120
[TBL] [Abstract][Full Text] [Related]
22. Role of the c-myc proto-oncogene in the proliferation of hereditary gingival fibromatosis fibroblasts.
Tipton DA; Woodard ES; Baber MA; Dabbous MKh
J Periodontol; 2004 Mar; 75(3):360-9. PubMed ID: 15088873
[TBL] [Abstract][Full Text] [Related]
23. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
25. c-Myc antisense oligonucleotides preserve smooth muscle differentiation and reduce negative remodelling following rat carotid arteriotomy.
Forte A; Galderisi U; De Feo M; Gomez MF; Esposito S; Santè P; Renzulli A; Agozzino L; Hellstrand P; Berrino L; Cipollaro M; Cotrufo M; Rossi F; Cascino A
J Vasc Res; 2005; 42(3):214-25. PubMed ID: 15849475
[TBL] [Abstract][Full Text] [Related]
26. Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides.
Junghans M; Loitsch SM; Steiniger SC; Kreuter J; Zimmer A
Eur J Pharm Biopharm; 2005 Jul; 60(2):287-94. PubMed ID: 15939239
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
Boffa LC; Cutrona G; Cilli M; Matis S; Damonte G; Mariani MR; Millo E; Moroni M; Roncella S; Fedeli F; Ferrarini M
Cancer Gene Ther; 2007 Feb; 14(2):220-6. PubMed ID: 17053816
[TBL] [Abstract][Full Text] [Related]
28. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
29. Growth inhibition of SK-MEL-30 human melanoma cells by antisense c-myc oligonucleotides delivered by poly(N-isopropylacrylamide)/ poly(ethyleneimine) copolymer.
Dinçer S; Oskay EK; Piskin AK; Zeybek ND; Pişkin E
J Tissue Eng Regen Med; 2010 Jun; 4(4):284-90. PubMed ID: 19967748
[TBL] [Abstract][Full Text] [Related]
30. Two antisense promoters in the immunoglobulin mu-switch region drive expression of c-myc in the Burkitt's lymphoma cell line BL67.
Apel TW; Mautner J; Polack A; Bornkamm GW; Eick D
Oncogene; 1992 Jul; 7(7):1267-71. PubMed ID: 1620543
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
32. Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression.
Albrecht T; Schwab R; Peschel C; Engels HJ; Fischer T; Huber C; Aulitzky WE
Ann Hematol; 1996 Feb; 72(2):73-9. PubMed ID: 8597610
[TBL] [Abstract][Full Text] [Related]
33. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
34. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
Smith MR; Abubakr Y; Mohammad R; Xie T; Hamdan M; al-Katib A
Cancer Gene Ther; 1995 Sep; 2(3):207-12. PubMed ID: 8528964
[TBL] [Abstract][Full Text] [Related]
35. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
36. [The effect of antisense H-ras on growth and metastasis of a high metastatic tumor model of human hepatoma in nude mice LCI-D20].
Liao Y; Tang Z; Sun F
Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):650-3. PubMed ID: 9275544
[TBL] [Abstract][Full Text] [Related]
37. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.
Stewart DA; Xu X; Thomas SD; Miller DM
Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846
[TBL] [Abstract][Full Text] [Related]
38. Quantifying c-myc expression in c-myc antisense phosphorothioate oligodeoxynucleotide-treated leukemic and colon cancer cell lines.
Li BD; Budnick RM; Russo CA; Anderson GR; Stewart CC
J Surg Res; 1995 Oct; 59(4):485-92. PubMed ID: 7564322
[TBL] [Abstract][Full Text] [Related]
39. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
40. A c-myc antisense oligonucleotide inhibits human retinal pigment epithelial cell proliferation.
Capeáns C; Piñeiro A; Domínguez F; Loidi L; Buceta M; Carneiro C; Garcia-Caballero T; Sanchez-Salorio M
Exp Eye Res; 1998 May; 66(5):581-9. PubMed ID: 9628805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
